发明名称 |
GLYPICAN-3 (GPC3)-DERIVED TUMOR REJECTION ANTIGENIC PEPTIDES USEFUL FOR HLA-A2-POSITIVE PATIENTS AND PHARMACEUTICAL COMPRISING THE SAME |
摘要 |
It is an object of the present invention to identify a glypican-3 -derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells. |
申请公布号 |
CA2619443(C) |
申请公布日期 |
2014.07.08 |
申请号 |
CA20062619443 |
申请日期 |
2006.08.08 |
申请人 |
KUMAMOTO UNIVERSITY |
发明人 |
NISHIMURA, YASUHARU;NAKATSURA, TETSUYA;KOMORI, HIROYUKI |
分类号 |
C07K14/705;A61K38/08;A61K38/17;A61P35/00;A61P37/04;C07K7/06;C07K16/28;C12N5/078;C12N5/0783;C12N15/00 |
主分类号 |
C07K14/705 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|